NCT04264533.

Study name	Vitamin C in vitamin C infusion for the treatment of severe 2019‐nCoV infected pneumonia
Methods	Design: randomised controlled trial Unit of randomisation: individually randomised
Participants	Location setting: Wuhan, China Sample size: 140 participants Sex: both Age: 18 years and older (adult, older adult) Inclusion criteria: ≥ 18 years old Diagnosed as serious or critical SARI (according to the 4th version of Diagnosis and Clinical Management of 2019‐nCoV infected pneumonia) Being treated in the ICU Exclusion criteria: Allergic to vitamin C Dyspnoea due to cardiogenic pulmonary oedema Pregnant or breastfeeding Life expectancy is less than 24 hours History of tracheotomy or home oxygen therapy Previously complicated with end‐stage lung disease, end‐stage malignancy, G6PD deficiency, diabetic ketoacidosis, and active kidney stone disease Concurrent participation in another clinical trial
Interventions	Intervention: experimental: vitamin C (24 g vitamin C + water for injection, total volume 50 mL. 7 mL/h; infusion pump) for 7 days Control: placebo comparator: water for injection (50 mL water for injection. 7 mL/h; infusion pump) for 7 days
Outcomes	Primary outcome: Ventilation‐free days Secondary outcomes: 28‐day mortality ICU length of stay Demand for first aid measurements Vasopressor days Respiratory indexes Ventilator parameters APACHE II scores SOFA scores
Starting date	10 February 2020
Contact information	Zhiyong Peng, Professor +8618672396028 pengzy5@hotmail.com
Notes	Not yet recruiting

APACHE: Acute Physiology and Chronic Health Evaluation
CAP: community‐acquired pneumonia
CURB‐65: confusion, urea > 7 mmol/L, respiratory rate ≥ 30 breaths/min, low blood pressure and age ≥ 65 years
G6PD: glucose‐6‐phosphate dehydrogenase
ICU: intensive care unit
IV: intravenous
SARI: severe acute respiratory infections
severe 2019‐nCoV: severe 2019 novel coronavirus
SOFA: Sequential Organ Failure Assessment